Cutter & CO Brokerage Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Cutter & CO Brokerage Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,173 shares of the biopharmaceutical company’s stock after purchasing an additional 180 shares during the period. Cutter & CO Brokerage Inc.’s holdings in Gilead Sciences were worth $338,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC purchased a new stake in Gilead Sciences during the fourth quarter valued at approximately $525,000. Linden Thomas Advisory Services LLC raised its holdings in Gilead Sciences by 6.7% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 34,134 shares of the biopharmaceutical company’s stock worth $2,765,000 after purchasing an additional 2,153 shares during the period. Parkside Financial Bank & Trust lifted its position in Gilead Sciences by 5.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,063 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 165 shares in the last quarter. PDS Planning Inc grew its holdings in Gilead Sciences by 4.3% during the fourth quarter. PDS Planning Inc now owns 4,426 shares of the biopharmaceutical company’s stock valued at $359,000 after purchasing an additional 182 shares during the period. Finally, RWA Wealth Partners LLC increased its position in Gilead Sciences by 0.8% in the fourth quarter. RWA Wealth Partners LLC now owns 33,204 shares of the biopharmaceutical company’s stock worth $2,690,000 after buying an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on GILD shares. Wells Fargo & Company cut their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday. Cantor Fitzgerald cut their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Finally, Royal Bank of Canada lowered their price objective on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 14th. Ten investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $84.57.

Gilead Sciences Price Performance

GILD traded down $0.05 during trading hours on Wednesday, hitting $66.98. The company’s stock had a trading volume of 3,576,879 shares, compared to its average volume of 7,250,059. The stock has a market cap of $83.40 billion, a price-to-earnings ratio of 14.89, a P/E/G ratio of 0.96 and a beta of 0.19. The business’s 50-day moving average price is $71.68 and its 200-day moving average price is $76.46. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $65.90 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter last year, the firm earned $1.67 earnings per share. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post 6.28 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.60%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.